January 21, 2020
Imaging markers of response to targeted therapies in BRAFV600E melanoma
Related publications :
- Acciardo S, Mignion L, Lacomblez E, Schoonjans C, Joudiou N, Gourgue F, Bouzin C, Baurain JF, Gallez B, Jordan BF. J Cell Mol Med. 2019 Dec 13. doi: 10.1111/jcmm.14890. Metabolic imaging using hyperpolarized 13 C-pyruvate to assess sensitivity to the B-Raf inhibitor vemurafenib in melanoma cells and xenografts.
- Acciardo S, Mignion L, Joudiou N, Bouzin C, Baurain JF, Gallez B, Jordan BF. Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas. Oncotarget. 2018 Mar 30;9(24):16832-16846. doi: 10.18632/oncotarget.24709.
Promotor : Bénédicte Jordan - Co-promotor : Jean-François Baurain